title: Atypical hearing loss in women with breast cancer receiving adjuvant treatment.
abstract: There are no reports of adjuvant treatments for early breast cancer causing hearing loss. Yet in this exploratory study 14/16 women who had received Fluorouracil, Epirubicin and Cyclophosphamide (FEC) chemotherapy regimen, 11 of whom also received endocrine treatment, had reduced hearing sensitivity, with 9/16 being atypical. It is not clear whether this finding is related to oestrogen reduction and/or ototoxicity but a more detailed investigation in this area is warranted given the large number of women with breast cancer who receive adjuvant treatments.
authors.affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Falmer, East Sussex, and Department of Audiology, Royal Sussex County Hospital, Brighton, UK. val@sussex.ac.uk
authors.forename: V
authors.initials: V
authors.lastname: Jenkins
authors.forename: H
authors.initials: H
authors.lastname: Beveridge
authors.forename: R
authors.initials: R
authors.lastname: Low
authors.forename: S
authors.initials: S
authors.lastname: Mitra
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects